Portal de Periódicos da CAPES

Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer

2017; Lippincott Williams & Wilkins; Volume: 198; Issue: 1 Linguagem: Inglês

10.1016/j.juro.2017.01.048

1527-3792

Tuomas P. Kilpeläinen, Dimitri Pogodin-Hannolainen, K. Kemppainen, Kirsi Talala, Jani Raitanen, Kimmo Taari, Paula Kujala, Teuvo L.J. Tammela, Anssi Auvinen,

Molecular Biology Techniques and Applications

No AccessJournal of UrologyAdult Urology1 Jul 2017Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer Tuomas P. Kilpeläinen, Dimitri Pogodin-Hannolainen, Kimmo Kemppainen, Kirsi Talala, Jani Raitanen, Kimmo Taari, Paula Kujala, Teuvo L.J. Tammela, and Anssi Auvinen Tuomas P. KilpeläinenTuomas P. Kilpeläinen Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland , Dimitri Pogodin-HannolainenDimitri Pogodin-Hannolainen Department of Urology, Kanta-Häme Central Hospital, Hämeenlinna, Finland , Kimmo KemppainenKimmo Kemppainen School of Health Sciences, University of Tampere, Tampere, Finland , Kirsi TalalaKirsi Talala Finnish Cancer Registry, Helsinki, Finland , Jani RaitanenJani Raitanen School of Health Sciences, University of Tampere, Tampere, Finland UKK Institute for Health Promotion Research, Tampere, Finland , Kimmo TaariKimmo Taari Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland , Paula KujalaPaula Kujala Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland , Teuvo L.J. TammelaTeuvo L.J. Tammela Department of Urology, University of Tampere, Tampere University Hospital, Tampere, Finland Department of Urology, Tampere University Hospital, Tampere, Finland , and Anssi AuvinenAnssi Auvinen School of Health Sciences, University of Tampere, Tampere, Finland View All Author Informationhttps://doi.org/10.1016/j.juro.2017.01.048AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Screening for prostate cancer remains controversial, although ERSPC (European Randomized Study of Screening for Prostate Cancer) showed a 21% relative reduction in prostate cancer mortality. The Finnish Randomized Study of Screening for Prostate Cancer, which is the largest component of ERSPC, demonstrated a statistically nonsignificant 16% mortality benefit in a separate analysis. The purpose of this study was to estimate the degree of contamination in the control arm of the Finnish trial. Materials and Methods: Altogether 48,295 and 31,872 men were randomized to the control and screening arms, respectively. The screening period was 1996 to 2007. The extent of prostate specific antigen testing was analyzed retrospectively using laboratory databases. The incidence of T1c prostate cancer (impalpable prostate cancer detected by elevated prostate specific antigen) was determined from the national Finnish Cancer Registry. Results: Approximately 1.4% of men had undergone prostate specific antigen testing 1 to 3 years before randomization. By the first 4, 8 and 12 years of followup 18.1%, 47.7% and 62.7% of men in the control arm had undergone prostate specific antigen testing at least once and in the screening arm the proportions were 69.8%, 81.1% and 85.2%, respectively. The cumulative incidence of T1c prostate cancer was 6.1% in the screening arm and 4.5% in the control arm (RR 1.21, 95% CI 1.13–1.30). Conclusions: A large proportion of men in the control arm had undergone a prostate specific antigen test during the 15-year followup. Contamination is likely to dilute differences in prostate cancer mortality between the arms in the Finnish screening trial. References 1 : Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet2014; 384: 2027. Google Scholar 2 : Overdiagnosis and overtreatment of prostate cancer. Eur Urol2014; 65: 1046. Google Scholar 3 : Health-related quality of life in the Finnish trial of screening for prostate cancer. Eur Urol2014; 65: 39. Google Scholar 4 : Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst2014; 107: 366. Google Scholar 5 : Screening for prostate cancer. Cochrane Database Syst Rev2013; 1: CD004720. Google Scholar 6 : Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol2010; 11: 725. Google Scholar 7 : Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst2013; 105: 719. Google Scholar 8 : Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol2013; 64: 530. Google Scholar 9 : Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012; 104: 125. Google Scholar 10 : Mortality results from a randomized prostate-cancer screening trial. N Engl J Med2009; 360: 1310. Google Scholar 11 : Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials2010; 7: 303. Google Scholar 12 : Reevaluating PSA Testing rates in the PLCO trial. N Engl J Med2016; 374: 1795. Google Scholar 13 : Data quality and quality control of a population based cancer registry. Experience in Finland. Acta Oncol1994; 33: 365. Google Scholar 14 Statistics Finland, 2016. Available at http://www.stat.fi/artikkelit/2014/art_2014-12-08_002.html?s=0. Accessed June 8, 2016. Google Scholar 15 : Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. J Urol2000; 164: 1216. Link, Google Scholar 16 : Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int2003; 92: 97. Google Scholar 17 : Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol2009; 62: 499. Google Scholar 18 : Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med1997; 16: 1017. Google Scholar 19 : Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol2009; 56: 584. Google Scholar 20 : The Finnish prostate cancer screening trial: analyses on the screening failures. Int J Cancer2015; 136: 2437. Google Scholar 21 : Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol2014; 65: 329. Google Scholar 22 : Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer2003; 105: 394. Google Scholar 23 : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360: 1320. Google Scholar 24 Engholm G, Ferlay J, Christensen N et al: NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.2 (16.12.2015). Association of the Nordic Cancer Registries. Danish Cancer Society. Available at http://www.ancr.nu. Accessed June 1, 2016. Google Scholar 25 : The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control2012; 23: 827. Google Scholar 26 : A system dynamics model of serum prostate-specific antigen screening for prostate cancer. Am J Epidemiol2016; 183: 227. Google Scholar © 2017 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byStinesen Kollberg K, Holmberg E, Josefsson A, Hugosson J and Arnsrud Godtman R (2022) Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1 Randomized, Population-Based, Prostate Cancer Screening TrialJournal of Urology, VOL. 208, NO. 5, (1018-1027), Online publication date: 1-Nov-2022.Smith J (2017) This Month in Adult UrologyJournal of Urology, VOL. 198, NO. 1, (1-2), Online publication date: 1-Jul-2017. Volume 198Issue 1July 2017Page: 50-57 Advertisement Copyright & Permissions© 2017 by American Urological Association Education and Research, Inc.Keywordsprostate-specific antigenmass screeningmortalitybiasprostatic neoplasmsMetricsAuthor Information Tuomas P. Kilpeläinen Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland Equal study contribution. More articles by this author Dimitri Pogodin-Hannolainen Department of Urology, Kanta-Häme Central Hospital, Hämeenlinna, Finland Equal study contribution. More articles by this author Kimmo Kemppainen School of Health Sciences, University of Tampere, Tampere, Finland More articles by this author Kirsi Talala Finnish Cancer Registry, Helsinki, Finland More articles by this author Jani Raitanen School of Health Sciences, University of Tampere, Tampere, Finland UKK Institute for Health Promotion Research, Tampere, Finland More articles by this author Kimmo Taari Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland More articles by this author Paula Kujala Fimlab Laboratories, Department of Pathology, Tampere University Hospital, Tampere, Finland More articles by this author Teuvo L.J. Tammela Department of Urology, University of Tampere, Tampere University Hospital, Tampere, Finland Department of Urology, Tampere University Hospital, Tampere, Finland More articles by this author Anssi Auvinen School of Health Sciences, University of Tampere, Tampere, Finland More articles by this author Expand All Advertisement PDF downloadLoading ...